NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
TSMC Posts Record Q1 2026 Profits Driven by Surging AI Chip Demand 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Jefferies Upgrades Starbucks to Hold as China JV Deal Closes and U.S. Business Shows Signs of Recovery 
CARLSBAD, Calif., Oct. 12, 2017 -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it will host an Analyst & Investor Event in Orlando, Florida on Thursday, October 26 from 7:00 a.m. to 9:00 a.m. E.T.
The meeting will include remarks from members of the SeaSpine leadership team on the company’s differentiated technologies and growth strategy, and commentary from key industry thought leaders.
A live webcast, including slide presentation, will be available on the SeaSpine website at www.investor.seaspine.com. An archived replay will also be available on the Company’s website following the meeting.
About SeaSpine
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implant portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implant product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Investor Relations Contact
Lynn Pieper Lewis
(415) 937-5402
[email protected]
